IL-6/JAK/STAT3/SOCS3 signaling pathway:potential therapeutic effect on inflammatory bowel disease
10.3760/cma.j.issn.1673-4408.2017.09.004
- VernacularTitle:IL-6/JAK/STAT3/SOCS3通路在炎症性肠病中的潜在治疗作用
- Author:
Yanyan ZHANG
1
Author Information
1. 中国医科大学附属盛京医院小儿消化内科
- Keywords:
Interleukin-6;
Janus kinase;
Signal transducer and activator of transcription 3;
Suppressor of cytokine signaling3;
Inflammatory bowel disease
- From:International Journal of Pediatrics
2017;44(9):599-601,606
- CountryChina
- Language:Chinese
-
Abstract:
Interleukin-6(IL-6)is a pleiotropic cytokine with central roles in immune and inflammatory reactions through downstream activation of the Janus kinase 2/signal transducer and activator of transcription 3 /Suppressor of cytokine signaling3 ( JAK/STAT3/SOCS3 ) signaling pathway. Additionally, dysregulation of the interleukin( IL)-6-mediated JAK/STAT3/SOCS3 signaling pathway is closely related to the development of in-flammatory bowel disease( IBD) . On this basis,modulation of the IL-6/JAK/STAT3/SOCS3 signaling pathway is currently being widely explored to develop novel therapies for IBD. The present review details the mechanisms and roles of the IL-6/JAK/STAT3/SOCS3 pathway in IBD, describes current therapeutic strategies, and the search for potential therapeutic approaches to treat IBD.